Vaccination therapy combined with chemotherapy for recurrent pancreatic cancer patients

复发性胰腺癌患者的疫苗接种联合化疗

• 批准号: 23592003
• 负责人: AOKI Taku
• 金额: $ 3.33万
• 依托单位: The University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23592003/
• 关键词: 膵癌; 樹状ワクチン治療; HSP105; 用量漸増試験; 有害事象; 有効性; 免疫学的評価; 樹状細胞ワクチン治療; ワクチン治療; 化学療法

A phase I trial of vaccination therapy using dendrite cells pulsed with HSP105 peptide was conducted. Inclusion criteria were patients with advanced/recurrent cancer with cancer tissue expressing HSP105 and with HLA-A2 or HLA-A24. Dosing-up protocols were applied using 5x106 DC cells/tretament (step 1), 1X107 DC cells/treatment (step 2), and 2X107 DC cells/ treatment (step 3).In the step 1, CD8 positive T cells specific for HSP105 were not recognized. In the step 2, DTH reaction was found in all the patients. Tumor response was SD in 1, and PD in 2. In the step 3, 4 patients with pancreatic cancer were the candidates, but only one patient received the therapy, as PS deteriorated in the other 3 patients. DTH reaction was also be found, but the tumor response was PD.

用HSP105多肽冲击的树突状细胞进行了疫苗治疗的I期试验。纳入标准为癌组织表达HSP105和人类白细胞抗原A2或人类白细胞抗原A24的晚期/复发癌症患者。剂量方案采用5×106 DC细胞/治疗(步骤1)、1×107 DC细胞/治疗(步骤2)和2×107 DC细胞/治疗(步骤3)。在步骤1中，未识别针对HSP105的CD8阳性T细胞。在步骤2中，所有患者均出现DTH反应。肿瘤反应：SD 1例，PD 2例。在第3步中，4例胰腺癌患者入选，但只有1例患者接受了治疗，其余3例PS恶化。也可见DTH反应，但肿瘤反应为PD。